Meeting
2015 ASCO Annual Meeting
Effect of itraconazole and rifampin on the pharmacokinetics of olaparib tablet formulation in patients with advanced solid tumours: Phase I open-label studies.
Authors
Elizabeth R. Plummer
Northern Centre for Cancer Care, Newcastle-upon-Tyne, United Kingdom
Elizabeth R. Plummer , Henk M.W. Verheul , Sylvie Rottey , Karin Leunen , Guy Heinrich Maria Jerusalem , Christian D. Rolfo , Dorte L. Nielsen , L Rhoda Molife , Rebecca Kristeleit , Judith de Vos-Geelen , Morten Mau-Sørensen , Patricia M.M.B. Soetekouw , Carla van Herpen , Helen Swaisland , Anitra Fielding , Karen So , Wendy Bannister , Luc Dirix
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Pharmacology
Clinical Trial Registration Number
NCT01900028/NCT01929603
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2565)
DOI
10.1200/jco.2015.33.15_suppl.2565
Abstract #
2565
Poster Bd #
281
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.
First Author: Funda Meric-Bernstam
Poster
2021 ASCO Annual Meeting
Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.
First Author: Vivek Subbiah
Poster
2021 ASCO Annual Meeting
A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.
First Author: Angela Tatiana Alistar
Poster
2020 ASCO Virtual Scientific Program
A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑3654 administered daily for 28 days to patients with advanced solid tumors.
First Author: Ignacio Garrido-Laguna